Navigation Links
Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
Date:3/8/2011

GREENSBORO, N.C., March 8, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced the launch of two programs to provide financial assistance to patients for their treatment with Xeomin® (incobotulinumtoxinA). XEOMIN is a botulinum toxin type A free from accessory proteins that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with cervical dystonia, to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naive and previously treated patients.  XEOMIN is also approved for the treatment of adults with blepharospasm who were previously treated with onabotulinumtoxinA (Botox®).

The XEOMIN Patient Co-payment Program is easy-to-use and offers eligible patients assistance for their actual out-of-pocket costs for therapeutic treatment with XEOMIN. Eligible treatment-related costs may include the cost of XEOMIN, associated guidance therapy and related administration fees.

Merz also announced the launch of the XEOMIN Patient Assistance Program, a program to provide XEOMIN at no cost to eligible patients who are experiencing financial hardship and who do not have third party drug coverage.

Enrollment in the XEOMIN Patient Co-payment Program or the XEOMIN Patient Assistance Program is simple. Patients who want to learn more about the programs and secure an application form can do so by calling 1-888-4-XEOMIN (1-888-493-6646) or by speaking with their healthcare provider. Dedicated support representatives are available from 8 a.m. until 8 p.m. (EST), Monday through Friday.

"By offering a continuum of XEOMIN financial assistance programs, our hope is to help patients manage their cervical dystonia and blepharospasm costs by reducing or eliminating financial obstacles that may prevent initiation or continuation of treatment," said Jack Britts, President and CEO of Merz Pharmaceuticals, LLC. "At Merz, we understand how difficult it can be to live with chronic cond
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
(Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... According to a study published today in PLOS ... world where malaria is common can mount an immune ... them to avoid repeated bouts of high fever and ... in their bloodstream. The findings may help researchers develop ... by the malaria parasite. , Each year, approximately 200 ...
(Date:4/17/2014)... Researchers at the University of California, San Diego School ... those who have suffered a recent major loss are ... older adults. , The study is published in this ... Psychiatry . , Because compassionate behaviors are associated with ... findings offer insights into ways to improve the outcomes ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2
... as other adults to attempt to end own life, study finds ... at birth are more likely to attempt suicide and more than ... normal-length newborns, a new study says. , Violent suicide includes hanging, ... height or in front of a vehicle, or drowning. , The ...
... COMPTCHE, Calif., Jan. 25 Wild Iris ... for healthcare professionals,( http://www.wildirismedicaleducation.com ) has just ... and more HMOs turn to telephone nursing ... health-related,problems by trained RNs using guidelines or ...
... Bmed, Ronit Calderon-Margalit, MD, MPH, Marianna Mazar, MD and ... to Jewish and Arab diabetes sufferers who were admitted ... evaluate whether differences existed between the two groups and, ... of health insurance coverage. The researchers found significant differences. ...
... following statement about next Monday,s vote on the health care,reform ... State Senate,Committee on Health:, "On behalf of AARP and ... the State Senate Health Committee to pass ABX 1 1 ... 1 represents a major step toward,ensuring that every Californian has ...
... 25 Super Bowl Sunday,s almost here-and,what better time ... losing some weight. Right? As more than 90 million ... event of the year, we,plan parties predicting the collapse ... With those big-guy pro,s gearing up for Super Bowl ...
... LOS ANGELES, Jan. 25 An unprecedented move,by ... it came to the table to settle two class ... Dec. 21, 2007 in Orange,County Superior Court, and one ... the Multnomah County Circuit Court and,should receive final approval ...
Cached Medicine News:Health News:Short Birth Length Boosts Men's Suicide Risk 2Health News:Telephone Nursing an Important Component of Managed Healthcare 2Health News:Super Bowl and SuperFoods: Play Smart 2Health News:Elder Care Operator and Plaintiff Attorney Announce Unprecedented Settlement Agreement in Class Action Lawsuit 2Health News:Elder Care Operator and Plaintiff Attorney Announce Unprecedented Settlement Agreement in Class Action Lawsuit 3
... visual field testing that's so efficient it,can ... first visual field instrument that's simple enough, ... used even in pre-test. Affordably priced FDT ... behind it to validate performance. The instrument ...
... Gore's EXCLUDER AAA Endoprosthesis is an innovative ... treatment option for patients with abdominal aortic ... durable ePTFE bifurcated graft with an outer ... device flexibility and material durability. The function ...
... (formerly sold as GORE Cast Liner) enables ... minimizing discomfort and other cast related nuisances. ... breathable, washable cast padding that replaces the ... cast. It allows patients the freedom to ...
... grafting or creation of a vascular access, ... is of the utmost importance in many ... for those seeking a high-precision tunneling instrument. ... risk of twisting or kinking for more ...
Medicine Products: